Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
Ying Li1,2 *, Jia-Jing Lu1,2 *, Xiao-Yuan Zhong1,2 *, Ying-Yuan Yu1,2 *, Ning Yu,1,2 Yu Wang,1,2 Xue-Mei Yi,1,2 Yang-Feng Ding,1,2 Yu-Ling Shi1,2 1Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Repub...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-10-01
|
| Series: | Clinical, Cosmetic and Investigational Dermatology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/drug-survival-outcomes-associated-with-the-real-world-use-of-ixekizuma-peer-reviewed-fulltext-article-CCID |
| _version_ | 1811344642655911936 |
|---|---|
| author | Li Y Lu JJ Zhong XY Yu YY Yu N Wang Y Yi XM Ding YF Shi YL |
| author_facet | Li Y Lu JJ Zhong XY Yu YY Yu N Wang Y Yi XM Ding YF Shi YL |
| author_sort | Li Y |
| collection | DOAJ |
| description | Ying Li1,2 *, Jia-Jing Lu1,2 *, Xiao-Yuan Zhong1,2 *, Ying-Yuan Yu1,2 *, Ning Yu,1,2 Yu Wang,1,2 Xue-Mei Yi,1,2 Yang-Feng Ding,1,2 Yu-Ling Shi1,2 1Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 2Institute of Psoriasis, Tongji University School of Medicine, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yu-Ling Shi; Yang-Feng Ding, Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, 1278 Road, Shanghai, 200443, People’s Republic of China, Email shiyuling1973@tongji.edu.cn; dingyangfeng@hotmail.comBackground: Data pertaining to biologic agents used for treating psoriasis in real-world settings are lacking at present. To compare drug survival at 52 weeks for a range of biologics used to treat psoriasis under real-world conditions.Methods: This was a retrospective, single-center, observational study of a cohort of patients diagnosed with plaque psoriasis treated using ixekizumab, secukinumab, guselkumab, or adalimumab between January 2020 and December 2021. Baseline demographic characteristics, duration of psoriasis, and prior biological treatments for all patients were recorded. Drug survival rates were analyzed in different patient groups using Kaplan–Meier curves and Log rank tests.Results: In total, this study included 386 plaque psoriasis patients, of whom 70, 175, 36, and 105 were, respectively, treated using ixekizumab, secukinumab, guselkumab, and adalimumab. Over a 52-week period, the overall cumulative drug survival rates for ixekizumab, secukinumab, guselkumab, and adalimumab were 67.1%, 63.0%, 72.2%, and 37.1%, respectively. Lack of efficacy was the primary cause of discontinuation for these biologic therapies, followed by economic burden and adverse event incidence.Conclusion: These results suggest that guselkumab exhibited superior drug survival, drug survival outcomes for ixekizumab and secukinumab were comparable, and significantly better than those of adalimumab in China. Preventing a loss of drug efficacy represents a primary approach to improving biologic drug survival in psoriasis patients.Keywords: biologics, drug survival, real-world, psoriasis, ixekizumab, secukinumab, guselkumab, adalimumab |
| first_indexed | 2024-04-13T19:51:13Z |
| format | Article |
| id | doaj.art-907528afcfd94acda818af4454b0cc9a |
| institution | Directory Open Access Journal |
| issn | 1178-7015 |
| language | English |
| last_indexed | 2024-04-13T19:51:13Z |
| publishDate | 2022-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical, Cosmetic and Investigational Dermatology |
| spelling | doaj.art-907528afcfd94acda818af4454b0cc9a2022-12-22T02:32:33ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152022-10-01Volume 152245225279105Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective StudyLi YLu JJZhong XYYu YYYu NWang YYi XMDing YFShi YLYing Li1,2 *, Jia-Jing Lu1,2 *, Xiao-Yuan Zhong1,2 *, Ying-Yuan Yu1,2 *, Ning Yu,1,2 Yu Wang,1,2 Xue-Mei Yi,1,2 Yang-Feng Ding,1,2 Yu-Ling Shi1,2 1Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 2Institute of Psoriasis, Tongji University School of Medicine, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yu-Ling Shi; Yang-Feng Ding, Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, 1278 Road, Shanghai, 200443, People’s Republic of China, Email shiyuling1973@tongji.edu.cn; dingyangfeng@hotmail.comBackground: Data pertaining to biologic agents used for treating psoriasis in real-world settings are lacking at present. To compare drug survival at 52 weeks for a range of biologics used to treat psoriasis under real-world conditions.Methods: This was a retrospective, single-center, observational study of a cohort of patients diagnosed with plaque psoriasis treated using ixekizumab, secukinumab, guselkumab, or adalimumab between January 2020 and December 2021. Baseline demographic characteristics, duration of psoriasis, and prior biological treatments for all patients were recorded. Drug survival rates were analyzed in different patient groups using Kaplan–Meier curves and Log rank tests.Results: In total, this study included 386 plaque psoriasis patients, of whom 70, 175, 36, and 105 were, respectively, treated using ixekizumab, secukinumab, guselkumab, and adalimumab. Over a 52-week period, the overall cumulative drug survival rates for ixekizumab, secukinumab, guselkumab, and adalimumab were 67.1%, 63.0%, 72.2%, and 37.1%, respectively. Lack of efficacy was the primary cause of discontinuation for these biologic therapies, followed by economic burden and adverse event incidence.Conclusion: These results suggest that guselkumab exhibited superior drug survival, drug survival outcomes for ixekizumab and secukinumab were comparable, and significantly better than those of adalimumab in China. Preventing a loss of drug efficacy represents a primary approach to improving biologic drug survival in psoriasis patients.Keywords: biologics, drug survival, real-world, psoriasis, ixekizumab, secukinumab, guselkumab, adalimumabhttps://www.dovepress.com/drug-survival-outcomes-associated-with-the-real-world-use-of-ixekizuma-peer-reviewed-fulltext-article-CCIDbiologicsdrug survivalreal-worldpsoriasisixekizumabsecukinumabguselkumabadalimumab. |
| spellingShingle | Li Y Lu JJ Zhong XY Yu YY Yu N Wang Y Yi XM Ding YF Shi YL Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study Clinical, Cosmetic and Investigational Dermatology biologics drug survival real-world psoriasis ixekizumab secukinumab guselkumab adalimumab. |
| title | Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study |
| title_full | Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study |
| title_fullStr | Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study |
| title_full_unstemmed | Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study |
| title_short | Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study |
| title_sort | drug survival outcomes associated with the real world use of ixekizumab secukinumab guselkumab and adalimumab for the treatment of plaque psoriasis in china a 52 week single center retrospective study |
| topic | biologics drug survival real-world psoriasis ixekizumab secukinumab guselkumab adalimumab. |
| url | https://www.dovepress.com/drug-survival-outcomes-associated-with-the-real-world-use-of-ixekizuma-peer-reviewed-fulltext-article-CCID |
| work_keys_str_mv | AT liy drugsurvivaloutcomesassociatedwiththerealworlduseofixekizumabsecukinumabguselkumabandadalimumabforthetreatmentofplaquepsoriasisinchinaa52weeksinglecenterretrospectivestudy AT lujj drugsurvivaloutcomesassociatedwiththerealworlduseofixekizumabsecukinumabguselkumabandadalimumabforthetreatmentofplaquepsoriasisinchinaa52weeksinglecenterretrospectivestudy AT zhongxy drugsurvivaloutcomesassociatedwiththerealworlduseofixekizumabsecukinumabguselkumabandadalimumabforthetreatmentofplaquepsoriasisinchinaa52weeksinglecenterretrospectivestudy AT yuyy drugsurvivaloutcomesassociatedwiththerealworlduseofixekizumabsecukinumabguselkumabandadalimumabforthetreatmentofplaquepsoriasisinchinaa52weeksinglecenterretrospectivestudy AT yun drugsurvivaloutcomesassociatedwiththerealworlduseofixekizumabsecukinumabguselkumabandadalimumabforthetreatmentofplaquepsoriasisinchinaa52weeksinglecenterretrospectivestudy AT wangy drugsurvivaloutcomesassociatedwiththerealworlduseofixekizumabsecukinumabguselkumabandadalimumabforthetreatmentofplaquepsoriasisinchinaa52weeksinglecenterretrospectivestudy AT yixm drugsurvivaloutcomesassociatedwiththerealworlduseofixekizumabsecukinumabguselkumabandadalimumabforthetreatmentofplaquepsoriasisinchinaa52weeksinglecenterretrospectivestudy AT dingyf drugsurvivaloutcomesassociatedwiththerealworlduseofixekizumabsecukinumabguselkumabandadalimumabforthetreatmentofplaquepsoriasisinchinaa52weeksinglecenterretrospectivestudy AT shiyl drugsurvivaloutcomesassociatedwiththerealworlduseofixekizumabsecukinumabguselkumabandadalimumabforthetreatmentofplaquepsoriasisinchinaa52weeksinglecenterretrospectivestudy |